Comments

Biogen Analyst Ratings

BIIBNASDAQ
Logo brought to you by Benzinga Data
Trade with Public
Trade with Public
$171.59
-2.21-1.27%
At close: Jan 23, 4:00 PM EST
$171.59
N/A
After Hours: 4:00 PM EST
Q4 2025 Earnings in 13 days from now on Fri Feb 6th, before the market open
OverviewNewsEarningsOptionsGuidance

Analyst Ratings

Insider TradesShort InterestGovernment TradesStock Report
Consensus Rating1
Neutral
Highest Price Target1
$292.00
Lowest Price Target1
$115.00
Consensus Price Target1
$190.39

Biogen Analyst Ratings and Price Targets | NASDAQ:BIIB | Benzinga

Biogen Inc has a consensus price target of $190.39 based on the ratings of 32 analysts. The high is $292 issued by Cantor Fitzgerald on September 9, 2024. The low is $115 issued by Piper Sandler on April 29, 2025. The 3 most-recent analyst ratings were released by Truist Securities, Citigroup, and UBS on January 8, 2026, January 7, 2026, and January 7, 2026, respectively. With an average price target of $185 between Truist Securities, Citigroup, and UBS, there's an implied 7.82% upside for Biogen Inc from these most-recent analyst ratings.

Analyst Trends and Forecast

1
2
Oct 25
1
2
Nov 25
2
Dec 25
2
Jan
Buy
Hold
Sell
Strong Sell

Analyst Rating and Forecast

12345
2.8
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Truist Securities
Citigroup
UBS
Morgan Stanley
Wells Fargo

1calculated from analyst ratings

Analyst Ratings for Biogen

Buy NowGet Alert
01/08/2026Buy Now10.73%Truist Securities$142 → $190MaintainsHoldGet Alert
01/07/2026Buy Now4.9%Citigroup$153 → $180MaintainsNeutralGet Alert
01/07/2026Buy Now7.82%UBS$130 → $185AssumesNeutral → NeutralGet Alert
12/12/2025Buy Now-9.09%Morgan Stanley$149 → $156MaintainsEqual-WeightGet Alert
12/10/2025Buy Now10.73%Wells Fargo$155 → $190MaintainsEqual-WeightGet Alert
12/10/2025Buy Now-16.66%HSBC$144 → $143DowngradeHold → ReduceGet Alert
11/21/2025Buy Now-8.5%Piper Sandler$118 → $157ReiteratesNeutral → NeutralGet Alert
11/06/2025Buy Now17.72%Stifel$144 → $202UpgradeHold → BuyGet Alert
11/03/2025Buy Now-8.5%Bernstein$155 → $157MaintainsMarket PerformGet Alert
10/31/2025Buy Now22.38%RBC Capital$217 → $210MaintainsOutperformGet Alert
10/14/2025Buy Now-10.83%Citigroup$135 → $153MaintainsNeutralGet Alert
10/10/2025Buy Now-13.17%Morgan Stanley$144 → $149MaintainsEqual-WeightGet Alert
09/25/2025Buy Now10.73%Jefferies → $190Initiates → BuyGet Alert
09/24/2025Buy Now—Needham—ReiteratesHold → HoldGet Alert
09/04/2025Buy Now—Needham—ReiteratesHold → HoldGet Alert
08/14/2025Buy Now-31.23%Piper Sandler$115 → $118MaintainsNeutralGet Alert
08/01/2025Buy Now-21.32%Citigroup$125 → $135MaintainsNeutralGet Alert
08/01/2025Buy Now27.63%RBC Capital$208 → $219MaintainsOutperformGet Alert
08/01/2025Buy Now-16.08%Morgan Stanley$146 → $144MaintainsEqual-WeightGet Alert
08/01/2025Buy Now13.06%HC Wainwright & Co.$187 → $194MaintainsBuyGet Alert
07/07/2025Buy Now21.22%RBC Capital$213 → $208MaintainsOutperformGet Alert
06/27/2025Buy Now24.13%RBC Capital$213 → $213ReiteratesOutperform → OutperformGet Alert
06/26/2025Buy Now8.98%HC Wainwright & Co.$187 → $187ReiteratesBuy → BuyGet Alert
06/25/2025Buy Now24.13%RBC Capital$205 → $213MaintainsOutperformGet Alert
06/12/2025Buy Now-32.98%Piper Sandler$115 → $115ReiteratesNeutral → NeutralGet Alert
06/12/2025Buy Now-29.48%Wedbush$121 → $121ReiteratesNeutral → NeutralGet Alert
06/12/2025Buy Now—Needham—ReiteratesHold → HoldGet Alert
05/07/2025Buy Now-1.51%Mizuho$207 → $169MaintainsOutperformGet Alert
05/05/2025Buy Now1.99%JP Morgan$185 → $175MaintainsNeutralGet Alert
05/02/2025Buy Now19.47%RBC Capital$217 → $205MaintainsOutperformGet Alert
05/02/2025Buy Now28.21%Canaccord Genuity$265 → $220MaintainsBuyGet Alert
05/02/2025Buy Now8.98%HC Wainwright & Co.$241 → $187MaintainsBuyGet Alert
05/02/2025Buy Now48.61%Baird$300 → $255MaintainsOutperformGet Alert
05/02/2025Buy Now—Needham—ReiteratesHold → HoldGet Alert
04/29/2025Buy Now15.97%Truist Securities$210 → $199MaintainsBuyGet Alert
04/29/2025Buy Now-32.98%Piper Sandler$135 → $115MaintainsNeutralGet Alert
04/25/2025Buy Now—Needham—ReiteratesHold → HoldGet Alert
04/23/2025Buy Now14.81%Goldman Sachs$219 → $197MaintainsBuyGet Alert
04/22/2025Buy Now31.13%RBC Capital$221 → $225MaintainsOutperformGet Alert
04/16/2025Buy Now-29.48%Wedbush$135 → $121MaintainsNeutralGet Alert
04/16/2025Buy Now—Needham—ReiteratesHold → HoldGet Alert
04/09/2025Buy Now-11.42%Morgan Stanley$157 → $152MaintainsEqual-WeightGet Alert
04/04/2025Buy Now—Argus Research—DowngradeBuy → HoldGet Alert
02/18/2025Buy Now-21.32%Piper Sandler$138 → $135ReiteratesNeutral → NeutralGet Alert
02/13/2025Buy Now30.54%Scotiabank$244 → $224MaintainsSector OutperformGet Alert
02/13/2025Buy Now-18.99%BMO Capital$156 → $139MaintainsMarket PerformGet Alert
02/13/2025Buy Now-8.5%Morgan Stanley$192 → $157MaintainsEqual-WeightGet Alert
02/13/2025Buy Now42.78%Goldman Sachs$281 → $245MaintainsBuyGet Alert
02/13/2025Buy Now31.13%RBC Capital$231 → $225MaintainsOutperformGet Alert
02/13/2025Buy Now-15.5%Citigroup$160 → $145MaintainsNeutralGet Alert
02/13/2025Buy Now-18.41%Wells Fargo$165 → $140MaintainsEqual-WeightGet Alert
02/13/2025Buy Now40.45%HC Wainwright & Co.$300 → $241MaintainsBuyGet Alert
02/13/2025Buy Now22.38%Truist Securities$220 → $210MaintainsBuyGet Alert
02/13/2025Buy Now54.44%Canaccord Genuity$298 → $265MaintainsBuyGet Alert
02/13/2025Buy Now—Needham—ReiteratesHold → HoldGet Alert
01/29/2025Buy Now-9.09%BMO Capital$164 → $156MaintainsMarket PerformGet Alert
01/28/2025Buy Now-6.75%Citigroup$190 → $160MaintainsNeutralGet Alert
01/10/2025Buy Now-3.84%Wells Fargo$190 → $165MaintainsEqual-WeightGet Alert
01/08/2025Buy Now28.21%Truist Securities$302 → $220MaintainsBuyGet Alert
01/02/2025Buy Now-19.58%Piper Sandler$315 → $138DowngradeOverweight → NeutralGet Alert
12/20/2024Buy Now-4.42%BMO Capital$230 → $164DowngradeOutperform → Market PerformGet Alert
12/10/2024Buy Now3.74%B of A Securities → $178Reinstates → NeutralGet Alert
12/09/2024Buy Now4.9%Jefferies$250 → $180DowngradeBuy → HoldGet Alert
12/05/2024Buy Now11.89%Morgan Stanley$204 → $192MaintainsEqual-WeightGet Alert
11/21/2024Buy Now20.64%Mizuho$251 → $207MaintainsOutperformGet Alert
11/18/2024Buy Now57.35%Needham$270 → $270DowngradeBuy → HoldGet Alert
11/15/2024Buy Now74.84%Baird$294 → $300MaintainsOutperformGet Alert
11/15/2024Buy Now—Wolfe Research—Initiates → Peer PerformGet Alert
11/14/2024Buy Now10.73%Citigroup → $190Initiates → NeutralGet Alert
11/04/2024Buy Now22.38%JP Morgan$220 → $210MaintainsNeutralGet Alert
10/31/2024Buy Now10.73%Wells Fargo$225 → $190MaintainsEqual-WeightGet Alert
10/31/2024Buy Now48.61%Oppenheimer$270 → $255MaintainsOutperformGet Alert
10/31/2024Buy Now4.9%Barclays$190 → $180MaintainsEqual-WeightGet Alert
10/31/2024Buy Now60.27%TD Cowen$300 → $275MaintainsBuyGet Alert
10/31/2024Buy Now74.84%HC Wainwright & Co.$300 → $300ReiteratesBuy → BuyGet Alert
10/31/2024Buy Now57.35%Needham$270 → $270ReiteratesBuy → BuyGet Alert
10/31/2024Buy Now18.89%Morgan Stanley$285 → $204DowngradeOverweight → Equal-WeightGet Alert
10/30/2024Buy Now57.35%Needham$270 → $270ReiteratesBuy → BuyGet Alert
10/17/2024Buy Now34.04%BMO Capital$260 → $230MaintainsOutperformGet Alert
10/10/2024Buy Now—Raymond James—Reinstates → Market PerformGet Alert
10/04/2024Buy Now56.77%RBC Capital$292 → $269MaintainsOutperformGet Alert
10/03/2024Buy Now17.72%UBS$234 → $202MaintainsNeutralGet Alert
09/24/2024Buy Now66.09%Needham$285 → $285ReiteratesBuy → BuyGet Alert
09/23/2024Buy Now19.47%Wedbush$210 → $205MaintainsNeutralGet Alert
09/19/2024Buy Now70.17%RBC Capital$292 → $292ReiteratesOutperform → OutperformGet Alert
09/09/2024Buy Now70.17%Cantor Fitzgerald$292 → $292ReiteratesOverweight → OverweightGet Alert
09/04/2024Buy Now66.09%Needham$285 → $285ReiteratesBuy → BuyGet Alert
08/19/2024Buy Now66.09%Needham$285 → $285ReiteratesBuy → BuyGet Alert
08/06/2024Buy Now46.28%Mizuho$277 → $251MaintainsOutperformGet Alert
08/05/2024Buy Now76%Truist Securities$340 → $302ReiteratesBuy → BuyGet Alert
08/05/2024Buy Now66.09%Needham$288 → $285MaintainsBuyGet Alert
08/02/2024Buy Now70.17%RBC Capital$282 → $292MaintainsOutperformGet Alert
08/02/2024Buy Now31.13%Wells Fargo$240 → $225MaintainsEqual-WeightGet Alert
08/02/2024Buy Now42.2%Scotiabank$275 → $244MaintainsSector OutperformGet Alert
08/02/2024Buy Now10.73%Barclays$200 → $190MaintainsEqual-WeightGet Alert
08/02/2024Buy Now22.38%Wedbush$215 → $210MaintainsNeutralGet Alert
08/01/2024Buy Now67.84%Needham$288 → $288ReiteratesBuy → BuyGet Alert
07/29/2024Buy Now71.34%Baird$316 → $294MaintainsOutperformGet Alert
07/26/2024Buy Now71.34%Needham$294 → $294ReiteratesBuy → BuyGet Alert
07/12/2024Buy Now82.41%Piper Sandler$335 → $313MaintainsOverweightGet Alert

FAQ

Q

What is the target price for Biogen (BIIB) stock?

A

The latest price target for Biogen (NASDAQ:BIIB) was reported by Truist Securities on January 8, 2026. The analyst firm set a price target for $190.00 expecting BIIB to rise to within 12 months (a possible 10.73% upside). 57 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Biogen (BIIB)?

A

The latest analyst rating for Biogen (NASDAQ:BIIB) was provided by Truist Securities, and Biogen maintained their hold rating.

Q

When was the last upgrade for Biogen (BIIB)?

A

The last upgrade for Biogen Inc happened on November 6, 2025 when Stifel raised their price target to $202. Stifel previously had a hold for Biogen Inc.

Q

When was the last downgrade for Biogen (BIIB)?

A

The last downgrade for Biogen Inc happened on December 10, 2025 when HSBC changed their price target from $144 to $143 for Biogen Inc.

Q

When is the next analyst rating going to be posted or updated for Biogen (BIIB)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biogen, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biogen was filed on January 8, 2026 so you should expect the next rating to be made available sometime around January 8, 2027.

Q

Is the Analyst Rating Biogen (BIIB) correct?

A

While ratings are subjective and will change, the latest Biogen (BIIB) rating was a maintained with a price target of $142.00 to $190.00. The current price Biogen (BIIB) is trading at is $171.59, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch

BeOne Medicines Ltd
NASDAQ:ONC
$338.98
-0.10%
Exact Sciences Corp
NASDAQ:EXAS
$102.10
-0.16%
Neurocrine Biosciences Inc
NASDAQ:NBIX
$136.18
%
Ionis Pharmaceuticals Inc
NASDAQ:IONS
$80.29
%
Roivant Sciences Ltd
NASDAQ:ROIV
$22.10
-2.13%
Amgen Inc
NASDAQ:AMGN
$344.63
-0.03%
United Therapeutics Corp
NASDAQ:UTHR
$468.94
%
BioNTech SE
NASDAQ:BNTX
$115.25
-0.63%
Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved